Europe's Oncology Pioneer Secures €12.5M Funding for ADC Breakthroughs
July 16, 2025, 9:35 pm
Oncomatryx Biopharma, a leading biotechnology firm, has secured a pivotal €12.5 million EIC Accelerator funding. This significant investment, a €2.5 million grant plus €10 million equity, underscores confidence in their oncology breakthroughs. Based in Bilbao, the company develops cutting-edge Antibody-Drug Conjugates (ADCs) for cancer therapy. Their lead candidate, OMTX705, precisely targets Fibroblast Activation Protein (FAP) in aggressive, immune-cold solid tumors like pancreatic, colorectal, and non-small cell lung cancers. Early clinical data from 95 patients in Phase I trials is highly promising. An outstanding safety profile emerged, with no dose-limiting toxicity. Patients expressing FAP showed sustained therapeutic responses. This funding accelerates Oncomatryx's R&D, expanding randomized clinical trials. It solidifies their role as Europe's premier ADC development platform, set to revolutionize hard-to-treat cancers. Oncomatryx was the only oncology company among 40 selected from 959 EIC Accelerator applicants, highlighting its unique scientific leadership and strategic importance in global cancer combat. This capital infusion ensures rapid progress for vital new targeted cancer drugs.
The European Innovation Council (EIC) Accelerator program represents a fiercely competitive arena. Only a select few companies receive its endorsement. Oncomatryx Biopharma emerged from a pool of 959 applications. Just 40 companies across 16 countries earned funding. Critically, Oncomatryx stood alone as the sole oncology company in this elite group. This distinction validates their innovative approach. It underscores the profound potential of their work in cancer therapy. The €12.5 million funding is a testament to this promise. It comprises a direct grant and a substantial equity investment. Such backing fuels critical research and development. It signals a major vote of confidence from the European Union.
Oncomatryx operates from Bilbao, Spain. Their mission focuses on next-generation Antibody-Drug Conjugates. These ADCs represent a powerful frontier in oncology. They combine targeted antibodies with potent therapeutic agents. This precise delivery minimizes systemic toxicity. It maximizes drug efficacy directly at tumor sites. Oncomatryx leverages a unique, proprietary ADC platform. This platform integrates novel payloads. It employs advanced conjugation formats. Their facilities are fully integrated. They encompass R&D, chemistry, and conjugation processes. This comprehensive capability sets them apart. It positions Oncomatryx as Europe’s most advanced ADC development platform. They span discovery through clinical-stage development. Their expertise extends to the tumor microenvironment. This deep biological understanding drives their innovative drug design. It makes them a strategic leader in oncology innovation.
The company's lead ADC candidate is OMTX705. This drug targets Fibroblast Activation Protein (FAP). FAP is a protein found in the stroma of many aggressive tumors. It plays a crucial role in tumor growth and metastasis. Targeting FAP allows for a precise attack on the tumor's supportive environment. This strategy is vital for cancers with high unmet medical needs. OMTX705 is currently undergoing clinical trials. Encouraging data emerged from these studies. Details were presented at the ASCO 2025 meeting.
Phase I clinical trials for OMTX705 have yielded compelling results. Ninety-five patients received treatment. These patients suffered from immune-cold metastatic solid tumors. The trial included dose escalation and backfilling cohorts. An outstanding safety profile was a key finding. Patients experienced no dose-limiting toxicity. This safety record is paramount in cancer treatment. Beyond safety, OMTX705 demonstrated significant efficacy. Patients expressing FAP showed sustained therapeutic responses. This indicates the drug's potential for durable benefits. These results provide a strong foundation. They support continued development and broader trials.
Randomized clinical trials are now underway. These trials expand the investigation of OMTX705. They focus on specific, challenging cancer types. These include immune-cold metastatic pancreatic cancer. Pancreatic cancer remains notoriously difficult to treat. OMTX705 also targets multisystem colorectal cancer (MSS). Non-small cell lung cancer (NSCLC) is another critical focus. These cancers represent areas of high unmet medical need. Current treatments often fall short. OMTX70x offers a new avenue. Its targeted approach holds significant promise for these patient populations.
Oncomatryx's importance extends beyond the EIC Accelerator. The company holds strategic designation. Both the Government of Spain and the Basque Regional Government recognize its value. Spain's R&D funding body, CDTI, through its Innvierte co-investment initiative, has invested directly. The Basque Regional Government has also provided direct investment. These endorsements acknowledge Oncomatryx’s pivotal role. They highlight its contribution to advancing oncology innovation. Combined with the EIC award, these investments solidify Oncomatryx’s standing. They firmly position the company as a European leader. This leadership spans both general oncology and the specialized ADC field.
The future of cancer treatment hinges on innovation. Targeted therapies offer profound advantages. They reduce side effects common with traditional chemotherapy. They increase the precision of drug delivery. Oncomatryx Biopharma embodies this future. Their focus on FAP-targeting ADCs is a strategic move. It addresses the biology of aggressive tumors. The ongoing clinical trials demonstrate tangible progress. Positive safety and efficacy data are encouraging. The financial backing from Europe and Spain is immense. It accelerates their mission. It brings new hope to patients. Millions globally await effective cancer treatments. Oncomatryx is poised to deliver. Its advancements could redefine the standard of care. This is a significant moment for cancer drug development. The world watches for their next breakthrough.
The European Innovation Council (EIC) Accelerator program represents a fiercely competitive arena. Only a select few companies receive its endorsement. Oncomatryx Biopharma emerged from a pool of 959 applications. Just 40 companies across 16 countries earned funding. Critically, Oncomatryx stood alone as the sole oncology company in this elite group. This distinction validates their innovative approach. It underscores the profound potential of their work in cancer therapy. The €12.5 million funding is a testament to this promise. It comprises a direct grant and a substantial equity investment. Such backing fuels critical research and development. It signals a major vote of confidence from the European Union.
Oncomatryx operates from Bilbao, Spain. Their mission focuses on next-generation Antibody-Drug Conjugates. These ADCs represent a powerful frontier in oncology. They combine targeted antibodies with potent therapeutic agents. This precise delivery minimizes systemic toxicity. It maximizes drug efficacy directly at tumor sites. Oncomatryx leverages a unique, proprietary ADC platform. This platform integrates novel payloads. It employs advanced conjugation formats. Their facilities are fully integrated. They encompass R&D, chemistry, and conjugation processes. This comprehensive capability sets them apart. It positions Oncomatryx as Europe’s most advanced ADC development platform. They span discovery through clinical-stage development. Their expertise extends to the tumor microenvironment. This deep biological understanding drives their innovative drug design. It makes them a strategic leader in oncology innovation.
The company's lead ADC candidate is OMTX705. This drug targets Fibroblast Activation Protein (FAP). FAP is a protein found in the stroma of many aggressive tumors. It plays a crucial role in tumor growth and metastasis. Targeting FAP allows for a precise attack on the tumor's supportive environment. This strategy is vital for cancers with high unmet medical needs. OMTX705 is currently undergoing clinical trials. Encouraging data emerged from these studies. Details were presented at the ASCO 2025 meeting.
Phase I clinical trials for OMTX705 have yielded compelling results. Ninety-five patients received treatment. These patients suffered from immune-cold metastatic solid tumors. The trial included dose escalation and backfilling cohorts. An outstanding safety profile was a key finding. Patients experienced no dose-limiting toxicity. This safety record is paramount in cancer treatment. Beyond safety, OMTX705 demonstrated significant efficacy. Patients expressing FAP showed sustained therapeutic responses. This indicates the drug's potential for durable benefits. These results provide a strong foundation. They support continued development and broader trials.
Randomized clinical trials are now underway. These trials expand the investigation of OMTX705. They focus on specific, challenging cancer types. These include immune-cold metastatic pancreatic cancer. Pancreatic cancer remains notoriously difficult to treat. OMTX705 also targets multisystem colorectal cancer (MSS). Non-small cell lung cancer (NSCLC) is another critical focus. These cancers represent areas of high unmet medical need. Current treatments often fall short. OMTX70x offers a new avenue. Its targeted approach holds significant promise for these patient populations.
Oncomatryx's importance extends beyond the EIC Accelerator. The company holds strategic designation. Both the Government of Spain and the Basque Regional Government recognize its value. Spain's R&D funding body, CDTI, through its Innvierte co-investment initiative, has invested directly. The Basque Regional Government has also provided direct investment. These endorsements acknowledge Oncomatryx’s pivotal role. They highlight its contribution to advancing oncology innovation. Combined with the EIC award, these investments solidify Oncomatryx’s standing. They firmly position the company as a European leader. This leadership spans both general oncology and the specialized ADC field.
The future of cancer treatment hinges on innovation. Targeted therapies offer profound advantages. They reduce side effects common with traditional chemotherapy. They increase the precision of drug delivery. Oncomatryx Biopharma embodies this future. Their focus on FAP-targeting ADCs is a strategic move. It addresses the biology of aggressive tumors. The ongoing clinical trials demonstrate tangible progress. Positive safety and efficacy data are encouraging. The financial backing from Europe and Spain is immense. It accelerates their mission. It brings new hope to patients. Millions globally await effective cancer treatments. Oncomatryx is poised to deliver. Its advancements could redefine the standard of care. This is a significant moment for cancer drug development. The world watches for their next breakthrough.